Document Detail


Novel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyond.
MedLine Citation:
PMID:  19262362     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Coronary artery disease, stroke, and peripheral vascular disease are known as "atherothrombotic" manifestations of atherosclerosis. These devastating conditions remain the major contributor of mortality and disability in a modern Western world, with estimated direct and indirect cost for 403.1 billion dollars in the United States alone. The application of current evidence-based therapy including the administration of low-dose aspirin and standard of care with clopidogrel proved to exhibit absolute mortality reduction in the randomized clinical trials International Study for Infarct Survival and Clopidogrel and Metoprolol in Myocardial Infarction Trial among patients after acute vascular events. However, these established antiplatelet medications have certain shortcomings including lack of efficacy in some patients, significant response variability, and potential "resistance." Therefore, intelligent development of novel oral antiplatelet agents is difficult to underestimate. In this review, we will focus on the developmental efforts with regard to the experimental agents such as adenosine diphosphate receptor blockers (prasugrel, ticagrelor, and cangrelor) and platelet glycoprotein VI adhesion antagonist [ProCorde GmbH 15 (PR-15)].
Authors:
Inna Shalito; Olga Kopyleva; Victor Serebruany
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of therapeutics     Volume:  16     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2009-12-04     Completed Date:  2010-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  451-8     Citation Subset:  IM    
Affiliation:
HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine / analogs & derivatives,  pharmacology,  therapeutic use
Adenosine Monophosphate / analogs & derivatives,  pharmacology,  therapeutic use
Administration, Oral
Animals
Atherosclerosis / drug therapy*,  physiopathology
Drug Design*
Humans
Piperazines / pharmacology,  therapeutic use
Platelet Aggregation Inhibitors / pharmacology,  therapeutic use*
Platelet Membrane Glycoproteins / antagonists & inhibitors
Receptors, Purinergic P2 / antagonists & inhibitors
Thiophenes / pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/AZD 6140; 0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Platelet Membrane Glycoproteins; 0/Receptors, Purinergic P2; 0/Thiophenes; 0/cangrelor; 0/platelet membrane glycoprotein VI; 0/prasugrel; 58-61-7/Adenosine; 61-19-8/Adenosine Monophosphate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of Medical Therapy on Left Ventricular Ejection Fraction in Patients With Systolic Heart Fail...
Next Document:  Intravenous Versus Epidural Analgesia After Surgical Repair of Pectus Excavatum.